A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)

Protocol No

SURG-BIOGEN-TRANSCEND

Staff Member

Matthew Cooper

Phase

III

Summary

This project is being done to learn more about the safety and/or effectiveness of felzartamab given to individuals who have been diagnosed with late antibody mediated rejection (AMR) following a kidney transplant.

Objective

Felzartamab for the Treatment of Late Antibody-Mediated Rejection in Kidney Transplant Recipients

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL